NCT03333343 - Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

January 29, 2018

Primary Completion Date

March 9, 2026

Study Completion Date

March 9, 2026

Conditions

EGFR-mutant Non-small Cell Lung Cancer

Interventions

DRUG

EGF816

Study Drug

DRUG

trametinib

Study Drug

DRUG

ribociclib

Study Drug

DRUG

LXH254

Study Drug

DRUG

INC280

Study Drug

DRUG

gefitinib

Study Drug

Trial Locations (11)

10002

Novartis Investigative Site, Taipei

20089

Novartis Investigative Site, Rozzano

20162

Novartis Investigative Site, Milan

45147

Novartis Investigative Site, Essen

50937

Novartis Investigative Site, Cologne

60126

Novartis Investigative Site, Ancona

70403

Novartis Investigative Site, Tainan City

119074

Novartis Investigative Site, Singapore

168583

Novartis Investigative Site, Singapore

999077

Novartis Investigative Site, Hong Kong

M5G 2M9

Novartis Investigative Site, Toronto